Tadal 20

Quick links to important sections

Tadal 20

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tadal 20

What is Tadal 20?

Tadal 20 is an oral medication primarily utilized for the treatment of erectile dysfunction (ED) in men. It contains the active pharmaceutical ingredient tadalafil, which belongs to a class of drugs known as phosphodiesterase type 5 (PDE5) inhibitors.

Mechanism of Action

The medication works by influencing the chemical response to sexual stimulation. Under normal conditions, sexual arousal leads to the release of nitric oxide in the erectile tissue of the penis. This process activates an enzyme that produces cyclic guanosine monophosphate (cGMP). The cGMP is responsible for relaxing the smooth muscle cells and increasing blood flow to the area, which facilitates an erection.

Tadalafil prevents the breakdown of cGMP by inhibiting the PDE5 enzyme. By maintaining higher levels of cGMP within the smooth muscle cells, the medication supports the physiological process required to achieve and maintain an erection suitable for sexual activity. It is important to note that the medication does not cause an erection in the absence of physical or psychological sexual stimuli.

Therapeutic Applications

While its most common application is the management of erectile dysfunction, the active ingredient in Tadal 20 is also used in different clinical contexts to treat other conditions related to smooth muscle relaxation and blood flow. These include:

  • Benign Prostatic Hyperplasia (BPH): Helping to relieve urinary symptoms, such as difficulty starting the flow of urine or the need to urinate frequently or urgently.
  • Pulmonary Arterial Hypertension: Improving exercise capacity by relaxing blood vessels in the lungs to lower blood pressure.

Pharmacokinetics

Tadalafil is characterized by its prolonged duration of action compared to other medications in the same class. Due to its metabolic profile, the effects of the medication can remain active in the body for an extended period, which has earned it a reputation for providing a wider window of opportunity for physical intimacy.

Regulatory References

  1. Tadalafil mechanism of action (NCBI Bookshelf)

What side effects are possible with Tadal 20?

Possible Side Effects and Safety Information

The safety profile of Tadal 20 is primarily defined by its vasodilatory effects. The following information is based on official governmental regulatory documents and clinical trials.

Common and Less Common Adverse Reactions

The most frequently reported adverse reactions (occurring in 1% or more of patients) include headache, dyspepsia (indigestion/heartburn), back pain, myalgia (muscle aches), nasal congestion, flushing, and pain in limb.

Less common reactions (occurring in 0.1% to < 1% of patients) may involve dizziness, gastroesophageal reflux, blurred vision, eye pain, palpitations, tachycardia, hypotension, hypertension, and tinnitus.


Serious and Clinically Significant Risks

Patients should be advised to stop treatment immediately and seek medical attention if they experience the following rare, serious events:

  • Priapism: A prolonged erection lasting four hours or longer. Untreated priapism can cause permanent damage.
  • Sudden Vision Loss: This may be a sign of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
  • Sudden Hearing Loss: May occur, sometimes accompanied by tinnitus or dizziness.
  • Severe Skin Reactions: Rare cases of Stevens-Johnson syndrome and exfoliative dermatitis have been reported.
  • Serious Cardiovascular Events: Post-marketing reports include myocardial infarction, unstable angina, and stroke.

Safety Restrictions and Contraindications

Tadal 20 is strictly contraindicated in patients who are simultaneously taking any form of organic nitrate (e.g., nitroglycerin) or a guanylate cyclase stimulator (e.g., riociguat) due to the risk of severe, life-threatening hypotension.

Caution is advised in individuals with certain pre-existing conditions, including uncontrolled hypertension, recent history of stroke or myocardial infarction (within 90 days), unstable angina, or specific anatomical deformities of the penis. Use is generally not recommended for patients with severe renal or hepatic impairment.

Overdose and Emergency Response

Overdose with Tadalafil is officially documented as presenting with an exaggeration of adverse events seen at lower doses. This may include an increased incidence and severity of common symptoms such as headache and dyspepsia. In clinical trials, single doses up to 500 mg showed adverse event profiles similar to therapeutic doses, but with greater severity.

Immediate medical assistance is required for several severe, documented outcomes. Patients must seek emergency treatment immediately if an erection lasts four hours or longer (Priapism), as this condition carries the risk of penile tissue damage and permanent loss of potency if untreated. Patients with conditions like sickle cell anemia, multiple myeloma, or leukemia are noted to be at increased risk for this severe outcome.

Additionally, patients must stop taking the medication and seek medical care immediately if they experience sudden loss of vision in one or both eyes or a sudden decrease or loss of hearing. These symptoms warrant urgent attention due to the potential for permanent sensory impairment.

For the management of Tadalafil overdose, no specific antidote is available. The official regulatory guidance directs that treatment must rely on standard supportive and symptomatic measures, as procedures like haemodialysis contribute negligibly to drug elimination.

Therapeutic Uses of Tadal 20

What Tadal 20 treats: main uses and benefits

Tadalafil is commonly used across therapeutic domains for managing symptoms that interfere with daily functioning, specifically erectile dysfunction (ED). This is a condition involving episodic or fluctuating manifestations, characterized by symptoms that create noticeable physiological strain. The medication may be part of symptomatic management in situations involving certain distressing symptoms of benign prostatic hyperplasia (BPH).

Tadalafil is considered relevant for easing symptoms that interfere with daily comfort in adult men for conditions such as erectile dysfunction and the signs and symptoms of BPH. For ED, this medication helps address symptom clusters associated with acute or episodic changes, and contributes to supportive relief when symptoms interfere with routine activities. For BPH, it may assist with easing lower urinary tract symptoms, such as difficulty or urgency with urination. Tadalafil is relevant in contexts involving heightened systemic burden where supportive symptom management is appropriate.

“This medication contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Relief for Symptoms that interfere with daily functioning

Regulatory References

  1. European Medicines Agency Cialis Overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Tadal 20 — Official Regulatory Information

The eligibility for Tadalafil 20 mg is strictly limited to adult men (18 years and older) for the approved male indications. Regulatory documents define several absolute prohibitions and restricted use cases based on patient condition and concurrent medications.


Populations for Whom Use is Contraindicated

Use of Tadal 20 is contraindicated (absolutely forbidden) in patients with the following conditions:

  • Patients taking any form of organic nitrate (e.g., nitroglycerin) or Guanylate Cyclase (GC) stimulators (e.g., riociguat).
  • Patients with known serious hypersensitivity to tadalafil.
  • Patients with a history of vision loss in one eye due to Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION).
  • Men whose underlying cardiac status makes sexual activity inadvisable, including those with recent myocardial infarction (last 90 days), unstable angina, recent stroke (last 6 months), or severe heart failure (NYHA Class 2 or greater).

Restricted Eligibility and Special Caution

Population Group Regulatory Status Restriction Note
Severe Hepatic Impairment (Child-Pugh Class C) Not recommended Insufficient clinical data; increased exposure.
Severe Renal Impairment (CrCl < 30 mL/min) Not recommended Not suitable for once-daily use; maximum as-needed dose is lower than 20 mg.
Priapism Predisposition Use with caution Patients with sickle cell anemia, multiple myeloma, or anatomical penile deformation.

Age and Gender Eligibility

  • Pediatric population (< 18 years): Not indicated for the approved male indications.
  • Adult Women: Not indicated for the approved male indications.
  • Pregnancy and Lactation: Should not be used (use is not established/recommended for these indications).

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns of Tadalafil (Tadal 20) as detailed in government regulatory information.

Classification Official Regulatory Description
Interaction severity classification Contraindicated Combinations; Significant Exposure Alteration; Risk of Symptomatic Hypotension.

Interaction Scope

  • Medicinal product categories with documented interactions: Organic Nitrates, Guanylate Cyclase (GC) Stimulators, Other PDE5 Inhibitors, Potent CYP3A4 Inhibitors, CYP3A4 Inducers, Alpha-Blockers, Antihypertensive Agents.
  • Specific interacting medicines (if explicitly listed): Riociguat (GC Stimulator), Ketoconazole (CYP3A4 Inhibitor), Ritonavir (CYP3A4 Inhibitor), Rifampicin (CYP3A4 Inducer).
  • Mechanistic basis of interactions (only if stated in label): Inhibition/Induction of CYP3A4 resulting in altered Tadalafil exposure (Pharmacokinetic Interaction). Additive vasodilatory/hypotensive effects (Pharmacodynamic Interaction).
  • Timing-based interaction rules (if applicable): A minimum of 48 hours must elapse after the last dose of Tadalafil before Organic Nitrates may be administered.
  • Interaction-related restrictions: Alcohol (ge 5 units) is documented to potentiate hypotensive effects. Grapefruit Juice is anticipated to increase plasma concentrations.

Official Interaction Statements

  • Co-administration is contraindicated with any form of Organic Nitrate, necessitating a mandatory 48-hour separation period.
  • Co-administration is contraindicated with Guanylate Cyclase (GC) stimulators (e.g., Riociguat) due to the documented risk of severe symptomatic hypotension.
  • Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir) are officially documented to increase Tadalafil exposure (AUC).
  • Potent CYP3A4 Inducers (e.g., Rifampicin) are officially documented to decrease Tadalafil exposure (AUC), anticipated to reduce efficacy.

Connection to the overall interaction profile (2–4 sentences): The official regulatory profile is defined by two primary safety constraints: absolute contraindication due to pharmacodynamic synergy (Nitrates and GC Stimulators), and significant pharmacokinetic interaction via the CYP3A4 metabolic pathway. These constraints necessitate explicit label warnings regarding prohibited co-administration and the management of exposure when combined with documented CYP3A4 inhibitors and inducers. The profile is further structured by documented pharmacodynamic interactions with agents like alpha-blockers, contributing to potential additive hypotension.

Mechanism of Action

How Tadal 20 Works

The mechanism of action for Tadal 20 (Tadalafil) is defined by its selective activity within the phosphodiesterase type 5 (PDE5) pathway. Tadalafil functions as a specific inhibitor of the PDE5 enzyme, which is responsible for the hydrolysis (breakdown) of the intracellular messenger, cyclic Guanosine Monophosphate (cGMP).

By blocking this enzymatic action, Tadalafil facilitates the accumulation of cGMP within the smooth muscle cells of certain tissues, notably blood vessel walls. This targeted action enhances the nitric oxide-cGMP signaling cascade, which is a key regulator of smooth muscle tone. The resulting sustained elevation of cGMP concentration drives a downstream molecular sequence that culminates in the relaxation of smooth muscle and vasodilation (widening of blood vessels), leading to an increase in localized blood flow.

Dosage and Administration Information

Tadal 20, containing Tadalafil, is administered exclusively by the oral route as a film-coated tablet. Official usage is defined by two primary regimens: use as needed (PRN) or once daily (continuous) dosing. The tablets should be swallowed whole without crushing or splitting, and intake is authorized with or without food. Efficacy for erectile dysfunction is conditional upon concurrent sexual stimulation.

Usage Feature Official Administration Guideline
Dosing Regimens PRN: Starting dose is 10 mg, adjustable from 5 mg to a maximum of 20 mg. Daily: Starting at 2.5 mg; maintained at 5 mg daily for BPH or chronic ED.
Frequency/Timing Maximum of once per day for all regimens. PRN doses should be taken at least 30 minutes prior to activity. Daily doses must be taken at approximately the same time each day.
Population Rules Older adults do not require routine adjustment. Dosage must be modified in cases of renal or hepatic impairment; daily use is typically not recommended for severe impairment.
Missed Dose Rule For the daily regimen, a missed dose should not be compensated for by taking a double dose at the next scheduled time.

These protocols strictly define the oral administration and regimen duality of Tadalafil. The rules establish specific maximum doses for intermittent use and mandate population-specific adjustments to standardize use for patients with impaired kidney or liver function. These explicit instructions govern the established boundaries of usage.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

The combination of two components has been studied to assess its effects. Studies have explored the potential for a reduction in symptoms with this combined therapy. Research has explored the effects of the combination therapy in individuals with chronic pain, including those who did not respond to other pain medications.


Component-Specific Research

Research has been conducted to examine the specific contributions of the two active ingredients.

Substance A

Studies have examined changes in reported pain levels associated with Substance A. In research trials, the effects of Substance A were typically evaluated over a defined treatment period.

Substance B

Research involving Substance B has been conducted. Research has explored the dose-response relationship of this component and its potential interaction with Substance A.


Pharmacokinetics and Absorption

Studies of the drug’s pharmacokinetics have examined its absorption when taken with food. Research also assessed the time it takes for the components to reach maximum concentration in the body.


Efficacy and Quality of Life

Clinical studies evaluated whether patient quality of life changed during the treatment period. Additional research examined outcomes across different patient populations, including those with varying levels of symptom severity. A recent meta-analysis compared the outcomes associated with the drug to those of other treatments.


Safety and Side Effects

Research investigated outcomes related to the safety of the drug over extended periods of use. Clinical trials evaluated the potential for side effects that may affect physical activities.

Key Studies & References

  1. Long-term Safety and Tolerability Study of Substance A/Substance B Combination Therapy in Patients with Non-Malignant Chronic Pain
  2. Clinical Practice Guideline for the Management of Chronic Musculoskeletal Pain (Focus on Multimodal Analgesia)

Frequently Asked Questions (FAQ)

Common questions about Tadal 20 (FAQ)


Q: How quickly does Tadal 20 typically start working after a dose?

A: Regulatory data indicates that the effect may begin as early as 30 minutes after administration. The maximum concentration of the medicine in the bloodstream is generally reached around two hours after the dose is taken.


Q: How long does the effect of a single Tadal 20 tablet usually last?

A: Official product information states that the effects have been shown to last for up to 36 hours following a single dose. This prolonged effect is related to the medicine's extended elimination time from the body.


Q: Is Tadal 20 the same as other medicines like Sildenafil, and what are the key differences?

A: Tadalafil is in the same class of medicines (PDE5 inhibitors) as Sildenafil. The medicine is characterized by a longer duration of activity compared to some other PDE5 inhibitors, based on its pharmacokinetic profile.


Q: What is the relationship between Tadal 20 and alcohol consumption?

A: Official labeling mentions that substantial alcohol consumption may increase the chance of additive vasodilatory effects. This could lead to symptoms like dizziness, headache, and a noticeable drop in standing blood pressure.


Q: Is Tadal 20 only for men, or are there uses for women in official documents?

A: The FDA and EMA approvals for Tadal 20 to treat erectile dysfunction and benign prostatic hyperplasia (BPH) are currently for adult men. Official regulatory information states the medicine is not indicated for these uses in women.


Q: Does Tadal 20 have any known effects on the color perception of objects?

A: Official documents note that uncommon vision changes have been reported. These include seeing a blue tinge when looking at objects and having difficulty distinguishing between the colors blue and green.


Q: Can Tadal 20 tablets be split or cut in half?

A: Regulatory instructions state that the medicine is formulated to be swallowed whole. The official conditions of use advise against crushing, splitting, or dividing the tablets prior to administration.


Q: What kind of vision changes are sometimes reported with Tadal 20?

A: Reported vision changes include blurred vision and eye pain. The labeling describes sudden decrease or loss of vision as a serious adverse event, often Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), which requires prompt medical evaluation.


Q: Does Tadal 20 work if there is no sexual stimulation?

A: Official regulatory information states that for the medicine to be effective in treating erectile dysfunction, the condition of sexual stimulation is necessary to facilitate its action. The drug acts by enhancing a natural response.


Q: Do side effects from Tadal 20 generally go away with continued use?

A: Official patient information indicates that common, mild side effects, such as headache or upset stomach, often resolve or lessen during the first few days or weeks of use. This is generally the case for common adverse reactions.


Q: Is it normal to experience muscle aches or back pain after taking Tadal 20?

A: Official regulatory documents list both back pain and muscle aches (myalgia) as common adverse reactions, reported by 1% or more of patients in clinical trials. Back pain is often reported 12 to 24 hours after a dose.


Q: Why is Tadal 20 sometimes called 'the weekend pill'?

A: The nickname is associated with Tadalafil’s long duration of activity. This long effect is due to its extended elimination time from the body, which differentiates it from some other medicines in the same class.


Q: Is it possible to take Tadal 20 for multiple days in a row?

A: The official maximum dosing constraint is once per day, regardless of the specific regimen (as-needed or daily use) intended for the patient.


Q: Does Tadal 20 increase a person's sexual desire or libido?

A: Tadal 20 is a PDE5 inhibitor that works by a physical mechanism (increasing blood flow) in certain tissues. Official documents describe the medicine's approved uses as relating to improving erectile function and do not describe it as directly affecting sexual desire or libido.


Q: Can Tadal 20 be used with other treatments for erectile dysfunction?

A: Official regulatory documents caution against the use of Tadal 20 alongside other PDE5 inhibitors or other concurrent treatments for erectile dysfunction.


Q: What are the official recommendations about what to do if a dose is missed?

A: For the daily-use regimen, the official guidance for a missed dose states that a double dose should not be taken to compensate for the forgotten dose at the next scheduled time.


Q: Is Tadal 20 available in other strengths besides 20mg?

A: The active ingredient, Tadalafil, is available in lower strengths in addition to the 20 mg tablet, for various approved uses including daily dosing and the treatment of BPH.


Q: How is Tadal 20 different from a daily-use Tadalafil product?

A: The 20 mg strength is typically used for as-needed dosing prior to activity. Daily-use formulations are usually lower strengths taken once a day, without regard to the timing of sexual activity.


Q: Is Tadal 20 officially approved for use in pulmonary hypertension in some countries?

A: The active ingredient in Tadal 20, Tadalafil, is approved by regulatory authorities for the treatment of pulmonary arterial hypertension (PAH). This approval is typically under a different trade name and involves a specific, higher daily dosing regimen.


Q: Can taking Tadal 20 cause a stuffy or blocked nose?

A: Nasal congestion or a stuffy nose is listed in official regulatory documents as one of the most common adverse reactions, reported by 1% or more of patients in clinical trials.


Q: How long after taking Tadal 20 is the peak concentration of the medicine reached?

A: The maximum concentration of the medicine in the bloodstream (Cmax) is typically reached around 2 hours after a single oral dose, based on pharmacokinetic studies.


Q: Is there a link between Tadal 20 and increased risk of bleeding?

A: Official labeling states that the medicine should be used with caution in patients with bleeding disorders or significant active peptic ulceration. However, studies in healthy subjects did not show an increase in bleeding time when co-administered with aspirin.


Q: Is Tadal 20 effective for men who have diabetes?

A: Clinical trials included men with diabetes. While official data noted a reduced exposure for this population compared to healthy subjects, regulatory information does not recommend a dose change based on diabetes status alone.


Q: Does Tadal 20 prevent the spread of sexually transmitted infections?

A: Official regulatory information explicitly states that the use of this medicine offers no protection against sexually transmitted infections (STIs), including HIV.


Q: Is Tadal 20 a cure for the condition it treats, or does it only manage symptoms?

A: Tadal 20 is classified as a treatment that manages the symptoms of the conditions it addresses, such as improving erectile function or reducing urinary issues related to BPH. Official documents do not describe it as a cure.


Q: What are the disposal requirements for Tadal 20 tablets?

A: Official guidelines recommend that unused or expired tablets be disposed of according to local regulatory requirements, such as utilizing a drug take-back program. The tablets should generally not be flushed down the toilet.

How should Tadal 20 be stored and disposed of?

Storage and Disposal Requirements

Tadalafil 20 mg tablets must be stored at room temperature and protected from moisture, as specified in regulatory labeling. To maintain product integrity, the medicine should be kept in its original container at all times. For safety, it is a mandatory requirement to store the product out of the sight and reach of children.

Disposal

Disposal of any unused or expired tablets must be performed in accordance with local regulatory requirements. Authorities like the FDA recommend using a drug take-back program as the preferred method. If a take-back option is unavailable, the tablets should be mixed with an undesirable substance (such as dirt) and sealed in a container before disposal in the household trash. Do not flush Tadalafil down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tadal 20 found in:

A-Z Index: